Original Policy Date
|
|
- Pierce Logan Small
- 5 years ago
- Views:
Transcription
1 MP Thyrgen (Thyrtrpin Alfa) Medical Plicy Sectin Prescriptin Drug Issue 12:2013 Original Plicy Date 12:2013 Last Review Status/Date Created with literature search/12:2013 Return t Medical Plicy Index Disclaimer Our medical plicies are designed fr infrmatinal purpses nly and are nt an authrizatin, r an explanatin f benefits, r a cntract. Receipt f benefits is subject t satisfactin f all terms and cnditins f the cverage. Medical technlgy is cnstantly changing, and we reserve the right t review and update ur plicies peridically. Descriptin Surgery is the crnerstne f management f patients with differentiated thyrid cancer. As an adjunct t this treatment, sme high-risk patients may need t underg radiactive idine treatment, further destrying nrmal thyrid tissue. All patients with tumrs arising frm fllicular epithelium require TSH suppressin since differentiated thyrid cancers cntain membrane receptrs respnsive t TSH. Lng-term thyrid hrmne supplements are used t maintain metablism in patients wh have had partial r ttal thyridectmy and/r radiactive idine treatment and t suppress endgenus levels f TSH. Management f patients with a histry f thyrid carcinma requires cntinuing evaluatin t mnitr cancer recurrence and metastatic disease by peridic physical examinatins, thyrglbulin levels, radiidine scans, and assurance f apprpriate TSH suppressin. A high level f TSH in a patient's bldstream is necessary t achieve ptimal sensitivity f serum thyrglbulin testing and in rder fr radiidine imaging t detect remnant thyrid tissue r metastatic disease. In rder t accmplish this, patients must stp taking their hrmne supplements fr tw t six weeks prir t testing. This thyrid hrmne withdrawal causes patients t experience symptms f hypthyridism -- fatigue, weight gain, cnstipatin, mental dullness, lethargy, depressin, and ther adverse reactins. On December 1, 1998, the FDA granted marketing apprval fr Thyrgen (thyrtrpin alfa) fr use as 'an adjunctive diagnstic tl fr serum thyrglbulin testing with r withut radiidine imaging in the fllw-up f patients with well-differentiated thyrid cancer.' Thyrgen, a recmbinant frm f TSH, prvides an external surce f TSH and allws thyrid cancer patients t avid hrmne withdrawal and its debilitating effects while underging diagnstic testing. The FDA made its decisin based n review f tw phase III clinical trials which were cnducted n 358 patients with well-differentiated thyrid cancer t cmpare 48-hur radiidine whle bdy scans btained after Thyrgen t whle bdy scans after thyrid hrmne withdrawal. One f these trials als cmpared thyrglbulin levels btained after Thyrgen t thse n thyrid hrmne suppressin therapy, and t thse after thyrid hrmne withdrawal. Acrss the tw clinical studies, Thyrgen was shwn t significantly enhance the sensitivity f thyrglbulin testing in patients maintained n thyrid hrmne therapy. The cmbinatin f a Thyrgen-stimulated scan and a serum thyrglbulin test did detect all patients with metastatic disease, althugh nt as sensitive as cmbinatin testing perfrmed after patients were 42 Memrial Drive Suite 1 Pinehurst, N.C Phne (910) Fax (910)
2 withdrawn frm thyrid hrmne supplements. The Thyrgen-stimulated scan failed t detect remnant and/r cancer lcalized t the thyrid bed in 16% (20/124) f patients in whm it was detected by a scan after thyrid hrmne withdrawal. In additin, the Thyrgen scan failed t detect metastatic disease in 24% (9/38) f patients in whm it was detected by a scan after thyrid hrmne withdrawal. Based n these studies, ne can cnclude that even when Thyrgen-stimulated thyrglbulin testing is perfrmed in cmbinatin with radiidine imaging, there remains a meaningful risk f missing a diagnsis f thyrid cancer r f underestimating the extent f disease. Recmbinant human thyrtrpin has als been demnstrated t be useful t facilitate radiidine ablatin f remnant thyrid tissue after surgery fr differentiated thyrid carcinma, as an alternative t thyrid hrmne withdrawal. After surgery fr differentiaed thyrid carcinma, many patients are treated with radiidine t ablate remnant thyrid tissue. This prcedure is mst cmmnly perfrmed with the patient in the hypthyrid state t prmte endgenus TSH stimulatin t ptmize radiidine uptake by remnant thyrid tissue. Hwever, thyrid hrmne withdrawal is assciated with hypthyrid symptms and impaired quality f life. Pacini, et al. (2006) reprted the results f a randmized cntrlled clinical trial t cmpare recmbinant human thyrtrpin t prepare patients n thyrid hrmne therapy t ablate remnant thyrid tissue with radiidine, cmpared with cnventinal remnant ablatin prefrmed in the hypthyrid state. The investigatrs fund cmparable remnant ablatin rates by administering recmbinant human thryrtrpin r by withhlding thyrid hrmne. Successful thyrid remnant ablatin was achieved by 23 f 24 patients (96 percent) treated with recmbinant human thyrtrpin, cmpared t 18 f 21 (86 percent) patients treated in the hypthyrid state (p = 0.23). The investigatrs reprted that subjects treated with recmbinant human thyrtrpin had a significantly higher quality f life during treatment than subjects treated in the hypthyrid state. The investigatrs reprted that subjects treated with recmbinant human thyrtrpin als had a significantly lwer radiatin expsure t the bld than patients treated in the hypthyrid state. Plicy Thyrgen (thyrtrpin alfa) is cnsidered medically necessary fr the fllwing patients with a histry f differentiated thyrid carcinma: Fr thyrglbulin (Tg) testing and radiidine imaging in place f thyrid hrmne withdrawal fr any f the fllwing: Patients wh wuld therwise be examined slely with a serum thyrglbulin test withut underging hrmne supplement withdrawal; r Patients with an undetectable Tg n thyrid hrmne suppressive therapy t exclude the diagnsis f residual r recurrent thyrid cancer; r Patients requiring serum Tg testing and radiidine imaging wh are unwilling t underg thyrid hrmne withdrawal testing and whse treating physician believes that use f a less sensitive test is justified; r Patients wh are either unable t munt an adequate endgenus thyrid stimulating hrmne (TSH) respnse t thyrid hrmne withdrawal; r Patients in whm withdrawal frm hrmne supplement is cntraindicated fr medical reasns. 42 Memrial Drive Suite 1 Pinehurst, N.C Phne (910) Fax (910)
3 T facilitate radiidine ablatin f remnant thyrid tissue after surgery fr differentiated thyrid carcinma, as an alternative t thyrid hrmne withdrawal. Thyrgen is cnsidered investigatinal fr all ther indicatins. Nte: Peridic thyrid hrmne withdrawal Tg testing, with r withut radiidine imaging, still remains the standard diagnstic mdality t assess the presence, lcatin and extent f thyrid cancer in persns wh have undergne surgery r radiactive idine treatment. References: 1. USAN Cuncil. List N New names. Thyrtrpin alfa. Clin Pharmacl Ther. 1998;64(1): Hrmann R. Recmbinant TSH and TSH analgs. Therapeutic implicatins? Internist (Berl). 1998;39(6): Utiger RD. Fllw-up f patients with thyrid carcinma. N Engl J Med. 1997;337(13): Ladensn PW, Braverman LE, Mazzaferri EL, et al. Cmparisn f administratin f recmbinant human thyrtrpin with withdrawal f thyrid hrmne fr radiactive idine scanning in patients with thyrid carcinma. N Engl J Med. 1997;337(13): Reynlds JC, Rbbins J. The changing rle f radiidine in the management f differentiated thyrid cancer. Semin Nucl Med. 1997;27(2): Rudavsky AZ, Freeman LM. Treatment f scan-negative, thyrglbulin-psitive metastatic thyrid cancer using radiidine 131I and recmbinant human thyrid stimulating hrmne. J Clin Endcrinl Metab. 1997;82(1): Ribela MT, Bianc AC, Bartlini P. The use f recmbinant human thyrtrpin prduced by Chinese hamster vary cells fr the preparatin f immunassay reagents. J Clin Endcrinl Metab. 1996;81(1): N authrs listed. M.D. Andersn studies drug fr thyrid cancer testing. Onclgy (Huntingt). 1996;10(6):820, David A, Bltta A, Bndanelli M, et al. Serum thyrglbulin cncentratins and (131)I whle-bdy scan results in patients with differentiated thyrid carcinma after administratin f recmbinant human thyrid-stimulating hrmne. J Nucl Med. 2001;42(10): Basaria M, Graf H, Cper DS. The use f recmbinant thyrtrpin in the fllw-up f patients with differentiated thyrid cancer. Am J Med. 2002;112(9): Ladensn PW. Recmbinant thyrtrpin fr detectin f recurrent thyrid cancer. Trans Am Clin Climatl Assc. 2002;113: Emersn CH, Trres MS. Recmbinant human thyrid-stimulating hrmne: Pharmaclgy, clinical applicatins and ptential uses. BiDrugs. 2003;17(1): Memrial Drive Suite 1 Pinehurst, N.C Phne (910) Fax (910)
4 13. Bmbardieri E, Seregni E, Villan C, et al. Recmbinant human thyrtrpin (rhtsh) in the fllw-up and treatment f patients with thyrid cancer. Tumri. 2003;89(5): Bauer DC. Review: Sensitive thyrtrpin testing in unselected inpatients has lw diagnstic accuracy. Evidence Based Med. 2000;5(1): British Thyrid Assciatin, Ryal Cllege f Physicians. Guidelines fr the management f thyrid cancer in adults. Lndn, UK: Ryal Cllege f Physicians; March Medical Services Advisry Cmmittee (MSAC). Recmbinant human thyrid stimulating hrmne (rhtsh). Diagnstic agent fr use in well-differentiated thyrid cancer. Assessment Reprt. MSAC Applicatin Canberra, ACT: AusInf; December Available at: Accessed August 8, Dagan T, Bedrin L, Hrwitz Z, et al. Quality f life f well-differentiated thyrid carcinma patients. J Laryngl Otl. 2004;118(7): Pichn Riviere A, Augustvski F, Cernadas C, et al. Benefits f recmbinant thyrid stimulating hrmne (rhtsh) in thyrid cancer fllw-up. Reprt IRR N. 21. Buens Aires, Argentina: Institute fr Clinical Effectiveness and Health Plicy (IECS); Kls RT. Papillary thyrid cancer: Medical management and fllw-up. Curr Treat Optins Oncl. 2005;6(4): Mernagh P, Campbell S, Dietlein M, et al. Cst-effectiveness f using recmbinant human TSH prir t radiidine ablatin fr thyrid cancer, cmpared with treating patients in a hypthyrid state: The German perspective. Eur J Endcrinl. 2006;155(3): Rbbins RJ, Driedger A, Magner J; U.S. and Canadian Thyrgen Cmpassinate Use Prgram Investigatr Grup. Recmbinant human thyrtrpin-assisted radiidine therapy fr patients with metastatic thyrid cancer wh culd nt elevate endgenus thyrtrpin r be withdrawn frm thyrxine. Thyrid. 2006;16(11): Pacini F, Ladensn PW, Schlumberger M, et al. Radiidine ablatin f thyrid remnants after preparatin with recmbinant human thyrtrpin in differentiated thyrid carcinma: Results f an internatinal, randmized, cntrlled study. J Clin Endcrinl Metab. 2006;91(3): Tuttle RM, Brkhin M, Omry G, et al. Recmbinant human TSH-assisted radiactive idine remnant ablatin achieves shrt-term clinical recurrence rates similar t thse f traditinal thyrid hrmne withdrawal. J Nucl Med. 2008;49(5): Brget I, Remy H, Chevalier J, et al. Length and cst f hspital stay f radiidine ablatin in thyrid cancer patients: Cmparisn between preparatin with thyrid hrmne withdrawal and thyrgen. Eur J Nucl Med Ml Imaging. 2008;35(8): Cdes Number Descriptin HCPCS J3240 Injectin, thyrtrpin alpha, 0.9 mg, prvided in 1.1 mg vial 42 Memrial Drive Suite 1 Pinehurst, N.C Phne (910) Fax (910)
5 42 Memrial Drive Suite 1 Pinehurst, N.C Phne (910) Fax (910)
Original Policy Date 12:2013
MP 5.01.18 Xlair (Omalizumab) Medical Plicy Sectin Prescriptin Drugs Issu12:2013e 4:2006 Original Plicy Date 12:2013 Last Review Status/Date Lcal plicy/12:2013 Return t Medical Plicy Index Disclaimer Our
More informationClinical Policy Bulletin: Thyrogen (Thyrotropin Alfa)
Thyrogen (Thyrotropin Alfa) Page 1 of 9 Clinical Policy Bulletin: Thyrogen (Thyrotropin Alfa) Number: 0515 Policy Aetna considers administration of Thyrogen (thyrotropin alfa) medically necessary for the
More informationCSHCN Services Program Benefits to Change for Outpatient Behavioral Health Services Information posted November 10, 2009
CSHCN Services Prgram Benefits t Change fr Outpatient Behaviral Health Services Infrmatin psted Nvember 10, 2009 Effective fr dates f service n r after January 1, 2010, benefit criteria fr utpatient behaviral
More informationRelated Policies None
Medical Plicy MP 3.01.501 Guidelines fr Cverage f Mental and Behaviral Health Services Last Review: 8/30/2017 Effective Date: 8/30/2017 Sectin: Mental Health End Date: 08/19/2018 Related Plicies Nne DISCLAIMER
More informationCLINICAL MEDICAL POLICY
Plicy Name: Plicy Number: Respnsible Department(s): CLINICAL MEDICAL POLICY Supervised Exercise Therapy fr Peripheral Artery Disease (PAD) MP-077-MD-DE Medical Management Prvider Ntice Date: 01/15/2019
More informationDrug Therapy Guidelines
Drug Therapy Guidelines Applicable* Hereditary Angiedema (HAE) Agents: Berinert (C1 esterase inhibitr [human]), Cinryze (C1 esterase inhibitr [human]), Haegarda (C1 esterase inhibitr [human]) Kalbitr (ecallantide),
More informationCardiac Rehabilitation Services
Dcumentatin Guidance N. DG1011 Cardiac Rehabilitatin Services Revisin Letter A 1.0 Purpse The Centers fr Medicare and Medicaid Services (CMS) has detailed specific dcumentatin requirements fr Cardiac Rehabilitatin
More informationNational Imaging Associates, Inc. (NIA) Frequently Asked Questions (FAQs) For Louisiana Healthcare Connections Providers
Natinal Imaging Assciates, Inc. (NIA) Frequently Asked Questins (FAQs) Fr Luisiana Healthcare Cnnectins Prviders Questin GENERAL Why did Luisiana Healthcare Cnnectins implement a Medical Prgram? Answer
More informationNational Imaging Associates, Inc. (NIA) Frequently Asked Questions (FAQs) For Managed Health Services (MHS)
Questin GENERAL Why did MHS implement a Medical Specialty Slutins Prgram? Natinal Imaging Assciates, Inc. (NIA) Frequently Asked Questins (FAQs) Fr Managed Health Services (MHS) Answer Effective Nvember
More informationNIA Magellan 1 Spine Care Program Interventional Pain Management Frequently Asked Questions (FAQs) For Medicare Advantage HMO and PPO
NIA Magellan 1 Spine Care Prgram Interventinal Pain Management Frequently Asked Questins (FAQs) Fr Medicare Advantage HMO and PPO Questin GENERAL Why is Flrida Blue implementing a Spine Management prgram
More informationNational Imaging Associates, Inc. (NIA) Frequently Asked Questions (FAQ s) For PA Health & Wellness Providers
Natinal Imaging Assciates, Inc. (NIA) Frequently Asked Questins (FAQ s) Fr PA Health & Wellness Prviders Questin GENERAL Why is PA Health & Wellness implementing a Medical Specialty Slutins Prgram? Answer
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synpsis fr Public Disclsure This clinical study synpsis is prvided in line with Behringer Ingelheim s Plicy n Transparency and Publicatin f Clinical Study Data. The synpsis which is
More informationCONSENT FOR KYBELLA INJECTABLE FAT REDUCTION
CONSENT FOR KYBELLA INJECTABLE FAT REDUCTION INSTRUCTIONS This is an infrmed cnsent dcument which has been prepared t help yur Dctr infrm yu cncerning fat reductin with an injectable medicatin, its risks,
More informationContinuous or Intermittent Monitoring of Glucose in Interstitial Fluid
Medical Plicy 1.01.20 Cntinuus r Intermittent Mnitring f Glucse in Interstitial Fluid Sectin 1.0 Durable Medical Equipment Subsectin Effective Date February 27, 2015 Original Plicy Date February 23, 2000
More informationCancer Association of South Africa (CANSA)
Cancer Assciatin f Suth Africa (CANSA) Fact Sheet and Psitin Statement n Cannabis in Suth Africa Intrductin Cannabis is a drug that cmes frm Indian hemp plants such as Cannabis sativa and Cannabis indica.
More informationHerbal Medicines: Traditional Herbal Registration
Herbal Medicines: Traditinal Herbal Registratin In the UK, cmpanies can nly sell herbal medicines with the apprpriate prduct licence, as fllws: A full marketing authrisatin based n the safety, quality
More informationDrug Therapy Guidelines
Applicable Medical Benefit x Effective: 5/1/18 Pharmacy- Frmulary 1 x Next Review: 3/18 Pharmacy- Frmulary 2 x Date f Origin: 4/99 Gnadtrpin-Releasing Hrmne Agnists- Eligard, Luprn, Luprn-Dept, Luprn Dept-Ped,
More informationOriginal Policy Date
MP 7.01.113 Orthgnathic Surgery Medical Plicy Sectin Surgery Issue 12/2013 Original Plicy Date 12/2013 Last Review Status/Date Lcal Plicy created 12/2013 Return t Medical Plicy Index Disclaimer Our medical
More information2018 Medical Association Poster Symposium Guidelines
2018 Medical Assciatin Pster Sympsium Guidelines Overview The 3 rd Annual student-run Medical Assciatin f the State f Alabama Research Sympsium will take place n Friday and Saturday, April 13-14 at the
More informationFDA Dietary Supplement cgmp
FDA Dietary Supplement cgmp FEBRUARY 2009 OVERVIEW Summary The Fd and Drug Administratin (FDA) has issued a final rule regarding current gd manufacturing practices (cgmp) fr dietary supplements that establishes
More informationBreast Cancer Awareness Month 2018 Key Messages (as of June 6, 2018)
Breast Cancer Awareness Mnth 2018 Key Messages (as f June 6, 2018) In this dcument there are tw sectins f messages in supprt f Cancer Care Ontari s Breast Cancer Awareness Mnth 2018: 1. Campaign key messages
More informationA foot x-ray series is required only if there is pain in the midfoot zone and any one of the following:
RADIOGRAPHY OF THE ANKLE AND FOOT (OTTAWA ANKLE RULES) Clinical Practice Guideline January 2007 This guideline has been adapted frm the Ottawa Ankle Rules develped by Dr. Ian Stiell et al. Dr. Stiell received
More informationCompleting the NPA online Patient Safety Incident Report form: 2016
Cmpleting the NPA nline Patient Safety Incident Reprt frm: 2016 The infrmatin cntained within this dcument is in line with the current Data Prtectin Act (DPA) requirements. This infrmatin may be subject
More informationP02-03 CALA Program Description Proficiency Testing Policy for Accreditation Revision 1.9 July 26, 2017
P02-03 CALA Prgram Descriptin Prficiency Testing Plicy fr Accreditatin Revisin 1.9 July 26, 2017 P02-03 CALA Prgram Descriptin Prficiency Testing Plicy fr Accreditatin TABLE OF CONTENTS TABLE OF CONTENTS...
More information1.11 INSULIN INFUSION PUMP MANAGEMENT INPATIENT
WOMEN AND NEWBORN HEALTH SERVICE CLINICAL GUIDELINES SECTION A: GUIDELINES RELEVANT TO OBSTETRICS AND GYNAECOLOGY 1 STANDARD PROTOCOLS 1.11 INSULIN INFUSION PUMP MANAGEMENT - INPATIENT Authrised by: OGCCU
More informationAnnex III. Amendments to relevant sections of the Product Information
Changes t the Prduct infrmatin as apprved by the CHMP n 13 Octber 2016, pending endrsement by the Eurpean Cmmissin Annex III Amendments t relevant sectins f the Prduct Infrmatin Nte: These amendments t
More informationHospital Preparedness Checklist
Hspital Preparedness Checklist http://pandemicflu.gv Preparedness Subject 1. Structure fr planning and decisin making An internal, multidisciplinary planning cmmittee fr influenza preparedness has been
More information2. How are screening and diagnostic mammograms different?
Mammgrams cmprises public dmain material frm the Natinal Cancer Institute at the Natinal Institutes f Health, an agency f the U.S. Department f Health and Human Services. Mammgrams Key Pints A mammgram
More informationLEVEL OF CARE GUIDELINES: INTENSIVE BEHAVIORAL THERAPY/APPLIED BEHAVIOR ANALYSIS FOR AUTISM SPECTRUM DISORDER HAWAII MEDICAID QUEST
OPTUM LEVEL OF CARE GUIDELINES: INTENSIVE BEHAVIORAL THERAPY / APPLIED BEHAVIOR ANALYSIS FOR AUTISM SPECTRUM DISORDER HAWAII MEDICAID QUEST LEVEL OF CARE GUIDELINES: INTENSIVE BEHAVIORAL THERAPY/APPLIED
More informationPREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland
AWARD NUMBER: W81XWH-14-1-0444 TITLE: Culd HER2 Hetergeneity Open New Therapeutic Optins in Patients with HER2- Primary Breast Cancer? PRINCIPAL INVESTIGATOR: Gary Ulaner, MD, PhD CONTRACTING ORGANIZATION:
More informationBenefits for Anesthesia Services for the CSHCN Services Program to Change Effective for dates of service on or after July 1, 2008, benefit criteria
Benefits fr Anesthesia Services fr the CSHCN Services Prgram t Change Effective fr dates f service n r after July 1, 2008, benefit criteria fr anesthesia will change fr the Children with Special Health
More informationPrior Authorization Review Panel MCO Policy Submission
Prior Authorization Review Panel MCO Policy Submission A separate copy of this form must accompany each policy submitted for review. Policies submitted without this form will not be considered for review.
More informationCommissioning Policy: South Warwickshire CCG (SWCCG)
Cmmissining Plicy: Suth Warwickshire CCG (SWCCG) Treatment Indicatin Criteria FreeStyle Libre Flash Cntinuus Glucse Mnitring System Type I Diabetes Prir apprval must be requested frm the Individual Funding
More informationObesity/Morbid Obesity/BMI
Obesity/mrbid besity/bdy mass index (adult) Obesity/Mrbid Obesity/BMI Definitins and backgrund Diagnsis cde assignment is based n the prvider s clinical judgment and crrespnding medical recrd dcumentatin
More informationBariatric Surgery FAQs for Employees in the GRMC Group Health Plan
Bariatric Surgery FAQs fr Emplyees in the GRMC Grup Health Plan Gergia Regents Medical Center and Gergia Regents Medical Assciates emplyees and eligible dependents wh are in the GRMC Grup Health Plan (Select
More informationRadiographic Procedures I Laboratory. o Work Experience, General. o Open Entry/Exit. Distance (Hybrid Online) for online supported courses
SECTION A - Curse Infrmatin 1. Curse ID: 2. Curse Title: 3. Divisin: 4. Department: 5. Subject: 6. Shrt Curse Title: 7. Effective Term:: RAD 61C Radigraphic Prcedures I Labratry Technlgy and Health Divisin
More informationCorporate Governance Code for Funds: What Will it Mean?
Crprate Gvernance Cde fr Funds: What Will it Mean? The Irish Funds Industry Assciatin has circulated a draft Vluntary Crprate Gvernance Cde fr the Funds Industry in Ireland. 1. Backgrund On 13 June 2011,
More informationACRIN 6666 Screening Breast US Follow-up Assessment Form
Screening Breast US Fllw-up Assessment Frm N. Instructins: The frm is cmpleted at 12, 24 and 36 mnths pst initial n study mammgraphy and ultrasund by the Radilgist r RA. Reprt all interim infrmatin related
More informationALCAT FREQUENTLY ASKED QUESTIONS
1. Is fasting required befre taking the Alcat Test? N. It is recmmended t drink water and t avid stimulants like caffeine prir t the test. 2. With regard t testing children, must a child be a certain age
More informationMGPR Training Courses Guide
MGPR Training Curses Guide fiscal cde 92107050921 1. Descriptin The training prgram supprted by MGPR is prpsed by a grup f excellent mentrs/educatrs, accmplished in Pesticides Management and Analysis,
More informationPolicy Guidelines: Genetic Testing for Carrier Screening and Reproductive Planning
Plicy Guidelines: Genetic Testing fr Carrier Screening and Reprductive Planning Cntents Overview... 1 Cverage guidelines... 2 General cverage guidelines... 2 Rutine carrier screening... 2 Carrier screening
More informationHealth Screening Record: Entry Level Due: August 1st MWF 150 Entry Year
Health Screening Recrd: Entry Level MIDWIFERY EDUCATION PROGRAM HEALTH SCREENING REQUIREMENTS (Rev. June 2017) 1. Hepatitis B: Primary vaccinatin series (3 vaccines 0, 1 and 6 mnths apart), plus serlgic
More informationTITLE: Managing Menopausal Symptoms in Breast Cancer Survivors
'.;* * AD GRANT NUMBER: DAMD17-94-J-4507 TITLE: Managing Menpausal Symptms in Breast Cancer Survivrs PRINCIPAL INVESTIGATOR: Patricia A. Ganz, M.D. CONTRACTING ORGANIZATION: University f Califrnia, Ls
More informationSpecifically, on page 12 of the current evicore draft, we find the statement:
Octber 23, 2016 evicre Healthcare Attn: Dr Greg Allen 400 Buckwalter Place Bulevard Blufftn, SC 29910 RE: evicre Draft Onclgy Imaging Guidelines, v 19.0 Gentlepersns: Prstate Cancer Internatinal is a nt-fr-prfit
More informationQ 5: Is relaxation training better (more effective than/as safe as) than treatment as usual in adults with depressive episode/disorder?
updated 2012 Relaxatin training Q 5: Is relaxatin training better (mre effective than/as safe as) than treatment as usual in adults with depressive episde/disrder? Backgrund The number f general health
More information2017 CMS Web Interface
CMS Web Interface PREV-5 (NQF 2372): Breast Cancer Screening Measure Steward: NCQA Web Interface V1.0 Page 1 f 18 11/15/2016 Cntents INTRODUCTION... 3 WEB INTERFACE SAMPLING INFORMATION... 4 BENEFICIARY
More informationBuilding Code 101 OWMC November 20, Ministry of Municipal Affairs and Housing
Building Cde 101 OWMC Nvember 20, 2015 Ministry f Municipal Affairs and Husing Disclaimer These slides are prvided by the Ministry f Municipal Affairs and Husing fr cnvenience nly The slides shuld nt be
More information23/11/2015. Introduction & Aims. Methods. Methods. Survey response. Patient Survey (baseline)
Intrductin & Aims Drug and Alchl Cnsultatin Liaisn (AOD CL) services aim t imprve identificatin and treatment f patients with AOD mrbidity. The csts and cnsequences f targeting AOD patients presenting
More informationWidening of funding restrictions for rituximab and eltrombopag
20 February 2014 Widening f funding restrictins fr rituximab and eltrmbpag PHARMAC is pleased t annunce the apprval f prpsals t widen the restrictin n rituximab use in DHB hspitals and expand the funding
More informationThe data refer to persons aged between 15 and 54.
Drug-related hspital stays in Australia 1993-2005 Prepared by Amanda Rxburgh and Luisa Degenhardt, Natinal Drug and Alchl Research Centre Funded by the Australian Gvernment Department f Health and Ageing
More informationCode of Conduct for Employees
Crprate Human Resurces Plicy Cntent Updated: 2016-06-22 Wrk Envirnment Plicy N: HR-01-09 Page 1 f 5 Apprval: 2014-09-24 Cde f Cnduct fr Emplyees POLICY STATEMENT The residents and businesses f the City
More informationReference: Patient A. Brenda WXXXXX Date of Birth: 4/15/57
Reference: Patient A Brenda WXXXXX Date f Birth: 4/15/57 49 year ld white female patient presented n July 20, 2006 with chief cmplaint f stage 4 cancer, initially diagnsed in Octber, 2003 with Cervical
More informationAncillary Symposia Request for Proposals Partner with the Endocrine Society to Educatte the Endocrine Community.
Ancillary Sympsia Request fr Prpsals Partnerr with the Endcrine Sciety t Educate the Endcrine Cmmunity. Jin the Endcrine Sciety in Bstn fr the 98 th Annual Meeting & Exp frm April 1 4, 2016. ENDO 2016
More informationIndications and Limitations of Coverage and/or Medical back to top
Fr services perfrmed n r after 09/15/2009 Original Determinatin Ending Date Revisin Effective Date Revisin Ending Date Indicatins and Limitatins f Cverage and/r Medical Necessity Indicatins Medicare cverage
More informationSafety of HPV vaccination: A FIGO STATEMENT
FIGO Statement n HPV Vaccinatin Safety, August 2nd, 2013 Safety f HPV vaccinatin: A FIGO STATEMENT July, 2013 Human papillmavirus vaccines are used in many cuntries; glbally, mre than 175 millin dses have
More informationChapter 6: Impact Indicators
Overview Chapter 6: Impact Indicatrs The best measure f the lng-term impact f all HIV preventin activities is the HIV incidence rate, namely the number f new cases f HIV infectin per year divided by the
More informationFee Schedule - Home Health Care- 2015
Fee Schedule - Hme Health Care- 2015 01/01/2015 1600 E Century Ave Ste 1 PO Bx 5585 Bismarck ND 58506-5585 www.wrkfrcesafety.cm Cpyright Ntice The five character cdes included in the Nrth Dakta Fee Schedule
More informationSolid Organ Transplant Benefits to Change for Texas Medicaid
Slid Organ Transplant Benefits t Change fr Texas Medicaid Infrmatin psted February 13, 2015 Nte: All new and updated prcedure cdes and their assciated reimbursement rates are prpsed benefits pending a
More informationInternational Myeloma Working Group Guidelines on Imaging Techniques in the Diagnosis and Monitoring of Multiple Myeloma 1
Internatinal Myelma Wrking Grup Guidelines n Imaging Techniques in the Diagnsis and Mnitring f Multiple Myelma 1 Up t 90% f myelma patients develp stelytic lesins, a majr cause f mrbidity and mrtality,
More informationCONTENTS Beyond Five
CONTENTS What is thyrid?... 2 What des the thyrid d?... 3 What is thyrid cancer?... 3 What causes thyrid cancer?... 4 What are the signs and symptms f thyrid cancer?... 5 Hw is thyrid cancer diagnsed?...
More informationCOVERAGE ELIGIBILITY OF SERVICES ASSOCIATED WITH A CANCER CLINICAL TRIAL
TRIAL Nn-Discriminatin Statement and Multi-Language Interpreter Services infrmatin are lcated at the end f this dcument. Cverage fr services, prcedures, medical devices and drugs are dependent upn benefit
More informationGUIDANCE DOCUMENT FOR ENROLLING SUBJECTS WHO DO NOT SPEAK ENGLISH
GUIDANCE DOCUMENT FOR ENROLLING SUBJECTS WHO DO NOT SPEAK ENGLISH Aurra Health Care s Research Subject Prtectin Prgram (RSPP) This guidance dcument will utline the prper prcedures fr btaining and dcumenting
More informationStudy Design Open, three arm-stratified, non-randomized, prospective, multicentric study
PONS Study Synpsis Title f the Study Subtype-Stratified Fllw-up Care Study f Breast Cancer Patients with Cmbined In Vitr and In Viv Diagnstics Plus Early Target-Oriented Interventin Gals Imprve and individualize
More informationCoronary Artery Disease (CAD): Beta Blocker Therapy for CAD Patients with Prior Myocardial Infarction (MI) (NQF 0070)
Crnary Artery Disease (CAD): Beta Blcker Therapy fr CAD Patients with Prir Mycardial Infarctin (MI) (NQF 0070) EMeasure Name Crnary Artery Disease EMeasure Id Pending (CAD): Beta Blcker Therapy fr CAD
More informationGuideline Number: NIA_CG_301 Last Revised Date: October 2014 Responsible Department: Implementation Date: October 2014 Clinical Operations
Natinal Imaging Assciates, Inc. Clinical guidelines PARAVERTEBRAL FACET JOINT INJECTIONS OR BLOCKS CPT Cdes: Cervical Thracic Regin: 64490 (+ 64491, +64492), 0213T (+0214T, +0215T) Lumbar Sacral Regin:
More informationOTHER AND UNSPECIFIED DISORDERS
OPTUM COVERAGE DETERMINATION GUIDELINE OTHER AND UNSPECIFIED DISORDERS Guideline Number: BH727OUD_102017 Effective Date: Octber, 2017 Table f Cntents Page INSTRUCTIONS FOR USE... 1 BENEFIT CONSIDERATIONS...
More informationWHAT IS HEAD AND NECK CANCER FACT SHEET
WHAT IS HEAD AND NECK CANCER FACT SHEET This infrmatin may help answer sme f yur questins and help yu think f ther questins that yu may want t ask yur cancer care team; it is nt intended t replace advice
More informationOsteoporosis Fast Facts
Osteprsis Fast Facts Fast Facts n Osteprsis Definitin Osteprsis, r prus bne, is a disease characterized by lw bne mass and structural deteriratin f bne tissue, leading t bne fragility and an increased
More informationContinuous Positive Airway Pressure (CPAP) and Respiratory Assist Devices (RADs) including Bi-Level PAP
Cntinuus Psitive Airway Pressure (CPAP) and Respiratry Assist Devices (RADs), Including Bi-Level PAP Benefit Criteria t Change fr Texas Medicaid Effective March 1, 2017 Overview f Benefit Changes Benefit
More information3903 Fair Ridge Drive, Suite 209, Fairfax, VA Harry Byrd Hwy, Suite 285, Ashburn, VA *How did you hear about our program?
3903 Fair Ridge Drive, Suite 209, Fairfax, VA 22033 44121 Harry Byrd Hwy, Suite 285, Ashburn, VA 220147 *Hw did yu hear abut ur prgram? Patient Histry Patient Name: First Middle: Last: Address: City: State:
More information2017 Optum, Inc. All rights reserved BH1124_112017
1) What are the benefits t clients f encuraging the use f MAT? Withut MAT, 90% f individuals with Opiid Use Disrder (OUD) will relapse within ne year. With MAT, the relapse rate fr thse with OUD decreases
More informationField Epidemiology Training Program
Field Epidemilgy Training Prgram Cancer Curriculum: Principles f Cancer Registries Case Study: Hspital-Based Cancer Registries FACILITATOR GUIDE FETP Cancer Curriculum: Principles f Cancer Registries Case
More informationASSESSMENT OF PITUITARY FUNCTION IN PATIENTS WITH SERUM PROLACTIN LEVELS GREATER THAN 100 NG/ML*t
FERTILITY AND STERILITY Cpyright 1979 The American Fertility Sciety Vl. 32, N.2, August 1979 Printed in U.s.A. ASSESSMENT OF PITUITARY FUNCTION IN PATIENTS WITH SERUM PROLACTIN LEVELS GREATER THAN 100
More informationNovel methods and approaches for sensing, evaluating, modulating and regulating mood and emotional states.
Nvel methds and appraches fr sensing, evaluating, mdulating and regulating md and emtinal states. 2018 Jy Academic Grant Call fr Prpsals Intrductin The Annual Jy grant initiative aims t prmte and cntribute
More informationStructured Assessment using Multiple Patient. Scenarios (StAMPS) Exam Information
Structured Assessment using Multiple Patient Scenaris (StAMPS) Exam Infrmatin 1. Preparing fr the StAMPS assessment prcess StAMPS is an assessment mdality that is designed t test higher rder functins in
More informationQP Energy Services LLC Hearing Conservation Program HSE Manual Section 7 Effective Date: 5/30/15 Revision #:
QP Energy Services LLC Hearing Cnservatin Prgram HSE Manual Sectin 7 Effective Date: 5/30/15 Revisin #: Prepared by: James Aregd Date: 5/30/15 Apprved by: James Aregd Date: 5/30/15 Page 1 f 8 Cntents Sectin
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial infrmatin prvided in this public disclsure synpsis is supplied fr infrmatinal purpses nly. Please nte that the results reprted in any single trial may nt reflect the verall ptential
More informationSUMMARY THE EUROPEAN COMMUNITY STRATEGY
SUMMARY THE EUROPEAN COMMUNITY STRATEGY FOR THE PHASEOUT OF CFCS IN MDIS 1. The Eurpean Cmmunity s transitin strategy fr the phaseut f CFCs in metered-dse inhalers (MDIs) was submitted t the Parties t
More informationThyroglobulin levels in serum and saliva of patients with differentiated thyroid carcinoma
Pre, Indian Acad. Sci., Vl. 87 B (Experimental Bilgy-J), N.7, July 1978. pp. 169-1". @ printed in India Thyrglbulin levels in serum and saliva f patients with differentiated thyrid carcinma D SHAH, S DANDEKAR
More informationHEALTH SURVEILLANCE INDICATORS: CERVICAL CANCER SCREENING. Public Health Relevance. Highlights.
HEALTH SURVEILLANCE INDICATORS: CERVICAL CANCER SCREENING Public Health Relevance Cervical cancer is 90% preventable by having regular Papaniclau (Pap) tests. The Pap test, als knwn as a cervical smear,
More informationMedical Policy Title: HDC & Autologous ARBenefits Approval: 02/08/2012
Medical Plicy Title: HDC & Autlgus ARBenefits Apprval: 02/08/2012 Stem&/r Prgenitr Cell Supprt, Germ Cell Tumrs Effective Date: 01/01/2013 Dcument: ARB0416:01 Revisin Date: 10/24/2012 Cde(s): 38230, Bne
More informationgoitre who present local compression symptoms.
Radiidine therapy in vluminus multindular nn-txic gitre Jean Vereist, Marc Bnnyns, and Daniel Gliner Departments f Internal Medicine and Radiistpes, University Hspital Saint-Pierre, Brussels, Belgium Abstract.
More informationEXECUTIVE SUMMARY INNOVATION IS THE KEY TO CHANGING THE PARADIGM FOR THE TREATMENT OF PAIN AND ADDICTION TO CREATE AN AMERICA FREE OF OPIOID ADDICTION
EXECUTIVE SUMMARY INNOVATION IS THE KEY TO CHANGING THE PARADIGM FOR THE TREATMENT OF PAIN AND ADDICTION TO CREATE AN AMERICA FREE OF OPIOID ADDICTION The Bitechnlgy Innvatin Organizatin (BIO) and ur member
More informationctdna-guided Change of Therapy Improves Quality of Life of a Lung Cancer Patient
CASE STUDY ctdna-guided Change f Therapy Imprves Quality f Life f a Lung Cancer Patient Quick Summary Tripti Vasudev*, aged 61 years, was diagnsed with NSCLC. Genetic analysis revealed the presence f an
More informationMethadone Maintenance Treatment for Opioid Dependence
POLICY STATEMENT Methadne Maintenance Treatment fr Opiid Dependence APPROVED BY COUNCIL: May 2010 PUBLICATION DATE: Dialgue, Issue 2, 2010 Disclaimer: As f May 19, 2018 physicians n lnger require an exemptin
More informationGuideline Number: NIA_CG_302 Last Revised Date: September 2015 Responsible Department: Implementation Date: September 2015 Clinical Operations
Natinal Imaging Assciates, Inc. Clinical guidelines PARAVERTEBRAL FACET JOINT DENERVATION (RADIOFREQUENCY NEUROLYSIS) CPT Cdes: Cervical Thracic Regin: 64633, +64634 Lumbar Sacral Regin: 64635, +64636
More informationReferral Criteria: Inflammation of the Spine Feb
Referral Criteria: Inflammatin f the Spine Feb 2019 1 5.7. Inflammatin f the Spine Backgrund Ankylsing spndylitis and axial spndylarthrpathy are fund in arund 0.3-1.2% f the ppulatin. Spndylarthritis encmpasses
More informationUS Public Health Service Clinical Practice Guidelines for PrEP
Webcast 1.3 US Public Health Service Clinical Practice Guidelines fr PrEP P R E S ENTED BY: M A R K T H R U N, M D A S S O C I AT E P R O F E S S O R, U N I V E R S I T Y O F C O L O R A D O, D I V I S
More informationOral Surgery (Facial Pain) Service Specification
Oral Surgery (Facial Pain) Service Specificatin Service Cmmissiner Lead Prvider Lead Perid 2. Oral Surgery Facial Pain (SBCH Ref N. SS_046) 1. Purpse 1.1 Aims T prvide a Cnsultant-led specialist diagnstic,
More informationFrequently Asked Questions: IS RT-Q-PCR Testing
Questins 1. What is chrnic myelid leukemia (CML)? 2. Hw des smene knw if they have CML? 3. Hw is smene diagnsed with CML? Frequently Asked Questins: IS RT-Q-PCR Testing Answers CML is a cancer f the bld
More informationAccess to Heme Treatment in Canada - Survey 2018
Access t Heme Treatment in Canada - Survey 2018 The Canadian Assciatin fr Prphyria/Assciatin Canadienne de Prphyrie (CAP/ACP) asserts that patients with acute prphyria shuld have access t Hemin treatment,
More informationDrug Class Review: Long-acting muscarinic antagonists (LAMAs) for treatment of chronic obstructive pulmonary disease (COPD)
Drug Class Review: Lng-acting muscarinic antagnists (LAMAs) fr treatment f chrnic bstructive pulmnary disease (COPD) Cmprehensive Research Plan: Pharmacepidemilgy Unit April 10 th, 2014 ODPRN Drug Class
More informationAppendix C. Master of Public Health. Practicum Guidelines
Appendix C Master f Public Health Practicum Guidelines 0 Gergia State University, Schl f Public Health Master f Public Health Practicum Guidelines Fr mre infrmatin, cntact Jessica Hwell Pratt, MPH Practicum
More informationPolicy. Medical Policy Manual Approved: Do Not Implement Until 1/1/18. Applied Behavioral Analysis (ABA)
Plicy Medical Plicy Manual Apprved: D Nt Implement Until 1/1/18 Applied Behaviral Analysis (ABA) This medical plicy will apply t self-funded grups upn their renewal, beginning 1/1/18. Des nt apply t BlueCare.
More informationEXPLORING THE PROCESS OF ASSESSMENT AND OTHER RELATED CONCEPTS
1 SECTION 1 INTRODUCTION: EXPLORING THE PROCESS OF ASSESSMENT AND OTHER RELATED CONCEPTS The Nature Of Assessment The Definitin Of Assessment The Difference Between Testing, Measurement And Evaluatin Characteristics
More informationProstatitis - chronic - Management
Prstatitis - chrnic - Management Scenari: Diagnsis f chrnic prstatitis Hw shuld I diagnse chrnic prstatitis? Diagnse chrnic prstatitis if: The man has pain in the perineum r pelvic flr and lwer urinary
More informationIndependent Charitable Patient Assistance Program (IPAP) Code of Ethics
Independent Charitable Patient Assistance Prgram (IPAP) Cde f Ethics Independent charitable patient assistance prgrams (IPAPs) fcus n the needs f patients wh are insured, meet certain financial limitatin
More informationImaging tests allow the cancer care team to check for cancer and other problems inside the body.
IMAGING TESTS This infrmatin may help answer sme f yur questins and help yu think f ther questins that yu may want t ask yur cancer care team; it is nt intended t replace advice r discussin between yu
More informationAnnual Principal Investigator Worksheet About Local Context
Cmpleting the NCI CIRB Annual Principal Investigatr Wrksheet Abut Lcal Cntext and the Study-Specific Wrksheet Abut Lcal Cntext at the University f Iwa All investigatrs cnducting research with the Natinal
More information2016 CWA Political Action Fund Administrative Procedures Checklist
2016 CWA Plitical Actin Fund Administrative Prcedures Checklist 1. Dates f Prgram The 2016 CWA Plitical Actin Fund (federal plitical actin cmmittee- CWA-COPE PCC) Prgram will be cnducted n a calendar year
More information